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Abstract 
Purpose: To investigate the anti-hyperprolactinemic activity of Prunella vulgaris L. extract (PVE) in vivo 
and in vitro. 
Methods: Rats were given intraperitoneal (i. p.) metoclopramide (MCP, 150 mg/kg daily) for 10 days to 
prepare hyperprolactinemia (hyperPRL) model. Bromocriptine was used as positive control drug. High 
(5.6 g/kg), medium (2.8 g/kg) and low (1.4 g/kg) doses of PVE were administered to hyperPRL rats. The 
effect of PVE on serum prolactin (PRL), estradiol (E2), progesterone (PGN), follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) levels were investigated in the rats. MMQ cells derived from rat 
pituitary adenoma cells and GH3 cells from rat pituitary lactotropictumoral cells were used for in vitro 
experiments. The effect of PVE on PRL secretion were studied in MMQ cells and GH3 cells 
respectively. 
Results: Compared with the control group (446.21 ± 32.43 pg/mL), high (219.23 ± 10.62 pg/mL) and 
medium (245.47 ± 13.52 pg/mL) reduced PRL level of hyperPRL rats significantly (p 0.05). In MMQ 
cells, treatment with 5 mg/mL PVE or 10 mg/mL PVE) significantly suppressed PRL secretion and 
synthesis at 24h compared with controls (p < 0.01). Consistent with D2- action, PVE did not affect PRL 
in rat pituitary lactotropic tumor-derived GH3 cells that lack the D2 receptor expression, compared with 
controls. 
Conclusion: PVE showed anti-hyperPRL activity and can potentially be used for the treatment of 
hyperprolactinemi, but further studies are required to ascertain this. 
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INTRODUCTION 
 
Hyperprolactinemia is the most common disorder 
of the hypothalamic-pituitary axis. Patients 
typically present with hypogonadism, infertility or, 
in the case of macroadenomas, symptoms 
related to mass effect (headache and visual field 
defects) [1]. The incidence rate of hyperPRL was 
0.4 % in the normal adult population and 9 -17 % 
in women with menstrual problems [2,3]. The two 
most commonly prescribed drugs in the 
treatment of hyperprolactinemia are bromo-
criptine and cabergoline. Both medications are 
dopamine receptor agonists and share many 
characteristics and adverse effects, such as 
headache, nausea and vomiting, among others, 
though frequency and severity of adverse effects 
appears to be less in cabergoline compared to 
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bromocriptine. It has been reported that 12 % 
patients cannot endure bromocriptine, which is 
one of the most widely used synthetic drugs in 
clinics [4]. 
 
Traditional Chinese medicine are often used for 
the treatment of hyperPRL [5]. Prunella vulgaris 
L. is a famous herb in China and widely used for 
treating hyperprolactinemia [6,7]. Most 
conventional anti-hyperPRL agents reduce PRL 
secretion through D2 receptor in the 
hypothalamic-neuroendocrine dopaminergic 
system [8]. Other sex steroids are also involved 
in the pathophysiology of hyperPRL [9]. In this 
study, the effects of PVE on serum hormone 
levels in hyperPRL rats and PRL secretion in 
cell-culture systems were investigated. MMQ cell 
derived from rat pituitary adenoma cells and GH3 
cell derived from rat pituitary lactotropictumoral 
cells were used.  
 
EXPERIMENTAL  
 
Preparation of PVE 
 
The dried herbs of Prunella vulgaris L. were 
mixed, and decocted with 1000 ml of water in a 
decocting pot twice, 45 min for each. The filtrate 
was mixed and concentrated into 200 ml liquor of 
PVE. It was then filtered through a 0.2 μm filter, 
and used for both in vitro and in vivo 
experiments. 
 
In vivo animal studies 
 
Female SD rats weighing 150 - 180 g were 
obtained from Zhejiang Center for Disease 
Control and Prevention, Hangzhou, Zhejiang. 
The animals had free access to feed and water, 
and were allowed to acclimatize for at least one 
week before use. All experiments were approved 
by the Animal Care and Use Committee of 
Zhejiang Cancer Hospital (approval ref no. 
20120622) and carried out in compliance with 
Directive 2010/63/EU on the handling of animals 
used for scientific purposes [10]. 
 
Rats were given intraperitoneal (i.p.) 
metoclopramide (MCP, 160 mg/kg body weight 
daily) for 10 days to prepare the model of 
hyperPRL [11]. 60 rats were randomly divided 
into six groups of ten rats: control, model group, 
bromocriptine-treated group, high-dose PVE-
treated (5.6 g/kg body weight) group, middle-
dose PVE-treated (2.8 g/kg body weight) group 
and low-dose PVE-treated (1.4 g/kg body weight) 
group. Each dose was dissolved in 2 mL water, 
and administered by gavage. The dosage was 
calculated from the human clinical dosage of 
PVE based on body surface area. Control and 
untreated model rats received 2 mL of saline. All 
the mice received treatment for 30 days. After 
the last treatment, serum PRL, E2, PGN, FSH 
and LH levels of the rats were measured by 
ELISA. 
 
Cell lines and cell culture studies 
 
MMQ cell and GH3 cell were used for in vivo 
experiments. MMQ cell was derived from rat 
pituitary adenoma cells, and GH3 cell was 
derived from rat pituitary lactotropic tumoral cells. 
Dose-dependent and time-course responses of 
PRL secretion and synthesis to PVE treatment 
were evaluated in MMQ cell line. 
 
MMQ cells were treated with PVE at 
concentrations of 1 - 10 mg/mL for 12 – 48 h. At 
different incubation time points, the culture 
medium was collected for measuring PRL 
secretion. Cells were collected for determining 
cellular PRL expression. The optimal 
concentrations and treatment duration were then 
determined for subsequent experiments. GH3 
were treated with PVE at effective concentrations 
that had been determined in MMQ cells for 24 h. 
The GH3 cells and medium were collected for 
the measurement of PRL secretion and 
expression respectively.  
 
Hormone assay 
 
Serum PRL, E2, PGN, FSH and LH 
concentrations of rat and PRL concentrations in 
the culture medium collected from MMQ and 
GH3 cells were measured using ELISA kits 
(Nanjing Jiancheng Biological Engineering Co, 
Ltd). 
 
Statistical analysis 
 
One- or two-way analysis of variance (ANOVA) 
was used to detect statistical significance, 
followed by post-hoc multiple comparisons 
(Student-Newman-Keuls method). Data are 
expressed as mean ± SEM. Statistical 
significance was defined as p < 0.05. 
 
RESULTS 
 
Effect of PVE on sex hormone levels in 
hyperPRL rats 
 
Compared with the control group, serum PRL 
level of hyperPRL model rats increased 
significantly (p < 0.01). Serum E2, PGN, FSH 
and LH levels of hyperPRL model rats decreased 
significantly (p < 0.01) after injecting 
metoclopramide in abdominal cavity. Compared 
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with the control group, the increased PRL level 
was significantly attenuated by treatment with 0.5 
mg/kg bromocriptine and 2.8 or 5.6 g/kg PVE 
after 30 days (p < 0.01). And rat serum E2 level 
increased (p < 0.01), and serum PGN, FSH and 
LH levels increased (p < 0.05) significantly in 
bromocriptine- treated group. Compared with the 
control group, rat serum E2 level increased (p < 
0.01), and serum P, FSH and LH levels 
increased (p < 0.05) significantly in high-dose of 
PVE group (Table 1). 
 
Effect of PVE on hyperactive PRL in MMQ and 
GH3 cells 
 
Two-way ANOVA analysis revealed a significant 
interaction between time course and treatment 
dose (F = 2.227, p = 0.042). Post-hoc multiple 
comparison further revealed that 1 and 10 
mg/mL PVE treatment for 24 and 36 h, but not 12 
and 48 h, produced significant suppression of 
PRL concentrations in the MMQ culture medium 
compared with controls (0 mg/mL) (p < 0.005) 
(Table 2). 24 h was then used in the latter 
experiment. PVE treatment for 24 h also yielded 
a significant suppression of MMQ cellular PRL 
expression in a dose-dependent manner (F = 
23.557, p < 0.001). Compared to control, the 
significant suppression was observed in the 
higher two concentrations (5 and 10 mg/mL) (p < 
0.003) (Tab. 2). The same concentrations did not 
produce significant effects on the medium 
concentration (F = 2.248, p = 0.136) and the 
cellular expression (F = 0.253, p = 0.812) in GH3 
cells (Table 3). 
 
DISCUSSION 
 
Hyperprolactinemia is a common 
endocrinological disorder that may be caused by 
several physiological and pathological conditions. 
Several drugs may determine a significant 
increase in prolactin serum concentration that is 
frequently associated with symptoms. In this 
study, we used the hyperPRL model of rats and 
two cell models to investigate the effect and 
action mechanism of PVE. MMQ cells, which 
express D2 receptor, are an excellent model of 
hyperPRL derived from rat pituitary adenoma 
cells responsive to dopamine [12]. Dose-
dependent and time-course responses of PRL 
secretion and synthesis to PVE treatment were 
evaluated in this cell line. GH3 cells were derived 
from rat pituitary lactotropictumoral cells that lack 
D2 receptor expression [13,14], which were used 
to determine if deficiency of D2 receptor saltered 
the suppression of PVE on hyperactive PRL.  
 
Table 1: Effect of PVE on sex hormone levels in hyperPRL rats 
 
Group PRL (pg/mL) 
E2 
(pmol/L) 
P 
(ng/mL) 
FSH 
(IU/L) 
LH 
(mIU/mL) 
Normal  227.32±7.34  3.62±0.28  1.18±0.07  0.83±0.05  1.77±0.15 
Control 446.21±32.43** 1.48±0.16** 0.48±0.16** 0.41±0.06** 0.86±0.08* 
Bromocriptine 218.37±9.85△  2.43±0.22△△ 0.81±0.04△ 0.78±0.04△ 1.71±0.06△ 
PVE-H  219.23±10.62△ 2.55±0.15△△ 0.92±0.06△ 0.71±0.03△ 1.48±0.18△ 
PVE-M  245.47±13.52△ 2.21±0.34△ 0.84±0.07△ 0.63±0.04△ 1.58±0.04△ 
PVE-L  317.36±39.58  1.93±0.39  0.63±0.14 0.49±0.06  1.37±0.11  
Data are expressed as mean ± SEM (n = 10) and analyzed using one-way ANOVA; *p < 0.05 and **p < 0.01 
versus control group; △p < 0.05 and △△p < 0.01 compared with model group; PVE-H: High-dose of PVE; PVE-M: 
Mid-dose of PVE; PVE-L: Low-dose of PVE 
 
          Table 2: Effect of WPRE on PRL secretion of MMQ cells at different time points 
 
PVE /(mg·mL-1) Time (h) 12 24 36 48 
0 1.53±0.02 1.85±0.01 1.69±0.02 1.38±0.01 
1 1.53±0.02 1.67±0.03 1.58±0.01 1.38±0.01 
5 1.53±0.02 1.49±0.02** 1.52±0.01* 1.38±0.01 
10 1.53±0.02 1.45±0.01** 1.46±0.03** 1.38±0.01 
            Compared with 0 mg/ml, *p < 0.05, **p < 0.01. 
 
           Table 3: Effect of WPRE on PRL secretion in GH3 cells 
 
Hormone PVE dose (mg/ml) 0 2 4 8 
PRL secretion ng/ml） 1.37±0.05 1.38±0.04 1.41±0.06 1.43±0.05 
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Consistent with D2-action, PVE did not affect 
PRL in rat pituitary lactotropic tumor-derived GH3 
cells that lack the D2 receptor expression. Our 
study result showed that D2 receptor is 
necessary for anti-hyperPRL activity of PVE. It 
suggest that D2 receptor played important roles 
in anti-hyperPRL activity of PVE. 
 
Dopamine receptors belong to the family of 
seven transmembrane domain G-protein coupled 
receptors (GPCR) [15-17].Dopamine receptors 
D1 and D2 are classified into two subtypes 
based on their differential effect on 
adenylylcyclase. 
 
Classically, the functions of dopamine receptors 
have been associated with the regulation of 
adenylate cyclase-protein kinase A through G-
protein-mediated signaling. Two classes of 
GPCR mediate dopamine functions, D1-like 
receptor sub-types (D1 and D5) couple mostly to 
Gas and stimulate the production of the second 
messenger cyclic adenosine monophosphate 
(cAMP) and the activity of protein kinase A 
(PKA). By contrast, D2-like subfamily (D2, D3 
and D4) couple to Gai/o and regulate the 
production of cAMP thus resulting in a diminution 
of PKA activity [18-20]. The physiological and 
pathological roles of DR2 have been recognized 
in some organs such as brain and kidney [21,22]. 
In the adenohypophysis, the predominant 
dopamine receptor is D2 receptor [23]. 
Transfection of the dopamine D2 receptor into a 
pituitary cell line results in a decrease in 
intracellular cAMP and inhibits prolactin secretion 
when dopamine is added to the cell culture [24]. 
Most conventional anti-hyperPRL agents reduce 
PRL secretion through D2 receptor in the 
hypothalamic neuroendocrine dopaminergic 
system. This study revealed that PVE showed 
anti-hyperPRL activity via dopamine D2 receptor. 
 
CONCLUSION 
 
The findings of the study indicate that Prunella 
vulgaris L. extract possesses anti-
hyperprolactinemic activity in vivo and in vitro, 
and therefore, can potentially be developed for 
therapeutic management of hyperprolactinemia. 
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